A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Hoffmann-La Roche
National Cancer Institute (NCI)
University of Nebraska
Mayo Clinic
Seagen Inc.
Dana-Farber Cancer Institute
SWOG Cancer Research Network
Dana-Farber Cancer Institute
University of Chicago
Pfizer
Fundacio Clinic Barcelona
University of California, San Francisco
Seagen Inc.
University of Nebraska
Dana-Farber Cancer Institute
City of Hope Medical Center
Dana-Farber Cancer Institute
City of Hope Medical Center
University of Alabama at Birmingham
Dana-Farber Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Texas Southwestern Medical Center
University of California, San Francisco
City of Hope Medical Center
City of Hope Medical Center
Astellas Pharma Inc
Dana-Farber Cancer Institute
Baylor Breast Care Center
Genentech, Inc.
Dana-Farber Cancer Institute
ETOP IBCSG Partners Foundation
Eli Lilly and Company
Seagen Inc.
Genentech, Inc.
Dana-Farber Cancer Institute
Hoffmann-La Roche
Case Comprehensive Cancer Center
Puma Biotechnology, Inc.
Merus B.V.
University of California, Irvine
Teva Branded Pharmaceutical Products R&D, Inc.
Hoffmann-La Roche
NYU Langone Health
Hoosier Cancer Research Network
Cancer Insight, LLC
Herlev Hospital
University of Southern California
University of Nebraska
Icahn School of Medicine at Mount Sinai
Seagen Inc.